NVAX EBITDA | NOVAVAX INC

NOVAVAX INC (NVAX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$54.91M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$15.43M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$178.02M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income $101.07M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2010-12-31 to 2025-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$54.91M	(m)	$56.70M	(m)	(m)	-$72.81M*	(m)	$70.69M	$26.66M	$1.71M
2026-03-31	Reported	(m)	-$15.43M	(m)	$139.51M	(m)	(m)	-$32.42M	(m)	$95.47M	$28.78M	$985.00K
2025-09-30	Reported	(m)	-$178.02M	(m)	$70.44M	(m)	(m)	$107.80M*	(m)	$98.27M	$31.66M	-$657.00K
2025-06-30	Reported	(m)	$101.07M	(m)	$239.24M	(m)	(m)	-$127.46M*	(m)	$79.23M	$43.61M	$946.00K
2025-03-31	Reported	(m)	$515.51M	(m)	$666.65M	(m)	(m)	-$185.50M	(m)	$88.94M	$48.09M	$1.20M
2024-09-30	Reported	(m)	-$134.02M	(m)	$84.51M	(m)	(m)	-$144.81M*	(m)	$87.16M	$70.75M	-$1.03M
2024-06-30	Reported	(m)	$161.00M	(m)	$415.48M	(m)	(m)	$314.27M*	(m)	$106.95M	(m)	$2.21M
2024-03-31	Reported	(m)	-$144.83M	(m)	$93.86M	(m)	(m)	-$83.56M	(m)	$92.68M	(m)	$2.26M
2023-09-30	Reported	(m)	-$125.63M	(m)	(m)	(m)	(m)	-$39.66M*	(m)	$106.23M	(m)	-$697.00K
2023-06-30	Reported	(m)	$55.46M	(m)	(m)	(m)	(m)	-$171.94M*	(m)	$219.47M	(m)	-$143.00K
2023-03-31	Reported	(m)	-$312.77M	(m)	(m)	(m)	(m)	-$325.59M	(m)	$247.10M	(m)	$1.18M
2022-09-30	Reported	(m)	-$127.19M	(m)	(m)	(m)	(m)	-$38.71M*	(m)	$304.30M	(m)	$2.47M
2022-06-30	Reported	(m)	-$482.96M	(m)	(m)	(m)	(m)	-$170.90M*	(m)	$289.65M	(m)	$1.42M
2022-03-31	Reported	(m)	$209.29M	(m)	(m)	(m)	(m)	-$88.51M	(m)	$383.48M	(m)	$2.66M
2021-09-30	Reported	(m)	-$307.14M	(m)	(m)	(m)	(m)	-$142.14M*	(m)	$408.19M	(m)	$6.04M
2021-06-30	Reported	(m)	-$345.83M	(m)	(m)	(m)	(m)	$144.41M*	(m)	$570.68M	(m)	$3.55M
2021-03-31	Reported	(m)	-$208.63M	(m)	(m)	(m)	(m)	$663.09M	(m)	$592.67M	(m)	$3.02M
2020-09-30	Reported	(m)	-$193.94M	(m)	(m)	(m)	(m)	-$6.50M*	(m)	$294.09M	(m)	$0.00
2020-06-30	Reported	(m)	-$17.03M	(m)	(m)	(m)	(m)	$115.63M*	(m)	$34.85M	(m)	$0.00
2020-03-31	Reported	(m)	-$22.90M	(m)	(m)	(m)	(m)	-$23.11M	(m)	$16.89M	(m)	$0.00
2019-09-30	Reported	(m)	-$14.99M	(m)	(m)	(m)	(m)	-$32.26M*	(m)	$18.61M	(m)	(m)
2019-06-30	Reported	(m)	-$36.67M	(m)	(m)	(m)	(m)	-$30.01M*	(m)	$30.42M	(m)	(m)
2019-03-31	Reported	(m)	-$40.22M	(m)	(m)	(m)	(m)	-$50.61M	(m)	$35.47M	(m)	(m)
2018-09-30	Reported	(m)	-$41.90M	(m)	(m)	(m)	(m)	-$33.51M*	(m)	$41.33M	(m)	(m)
2018-06-30	Reported	(m)	-$41.99M	(m)	(m)	(m)	(m)	-$39.97M*	(m)	$44.54M	(m)	(m)
2018-03-31	Reported	(m)	-$43.51M	(m)	(m)	(m)	(m)	-$66.08M	(m)	$44.51M	(m)	(m)
2017-09-30	Reported	(m)	-$41.63M	(m)	(m)	(m)	(m)	-$44.18M*	(m)	$41.86M	(m)	(m)
2017-06-30	Reported	(m)	-$41.47M	(m)	(m)	(m)	(m)	-$12.40M*	(m)	$39.26M	(m)	(m)
2017-03-31	Reported	(m)	-$40.83M	(m)	(m)	(m)	(m)	-$44.50M	(m)	$37.65M	(m)	(m)
2016-09-30	Reported	(m)	-$63.31M	(m)	(m)	(m)	(m)	(m)	(m)	$52.98M	(m)	(m)
2016-06-30	Reported	(m)	-$76.50M	(m)	(m)	(m)	(m)	(m)	(m)	$64.90M	(m)	(m)
2016-03-31	Reported	(m)	-$75.26M	(m)	(m)	(m)	(m)	(m)	(m)	$68.95M	(m)	(m)
2015-09-30	Reported	(m)	-$33.20M	(m)	(m)	(m)	(m)	(m)	(m)	$30.66M	(m)	(m)
2015-06-30	Reported	(m)	-$20.82M	(m)	(m)	(m)	(m)	(m)	(m)	$27.73M	(m)	(m)
2015-03-31	Reported	(m)	-$24.31M	(m)	(m)	(m)	(m)	(m)	(m)	$28.35M	(m)	(m)
2014-09-30	Reported	(m)	-$19.79M	(m)	(m)	(m)	(m)	(m)	(m)	$19.22M	(m)	(m)
2014-06-30	Reported	(m)	-$17.85M	(m)	(m)	(m)	(m)	(m)	(m)	$15.20M	(m)	(m)
2014-03-31	Reported	(m)	-$14.38M	(m)	(m)	(m)	(m)	-$20.43M	(m)	$14.52M	(m)	(m)
2013-09-30	Reported	(m)	-$15.28M	(m)	(m)	(m)	(m)	-$14.88M*	(m)	$13.95M	(m)	$0.00*
2013-06-30	Reported	(m)	-$12.90M	(m)	(m)	(m)	(m)	-$7.63M*	(m)	$10.79M	(m)	$5.00K
2013-03-31	Reported	(m)	-$10.01M	(m)	(m)	(m)	(m)	-$10.58M	(m)	$9.26M	(m)	$17.00K
2012-09-30	Reported	(m)	-$6.85M	(m)	(m)	(m)	(m)	-$4.63M*	(m)	$6.64M	(m)	(m)
2012-06-30	Reported	(m)	-$5.86M	(m)	(m)	(m)	(m)	-$6.13M*	(m)	$5.37M	(m)	(m)
2012-03-31	Reported	(m)	-$7.47M	(m)	(m)	(m)	(m)	-$4.22M	(m)	$5.34M	(m)	(m)
2011-09-30	Reported	(m)	-$3.97M	(m)	(m)	(m)	(m)	-$3.32M*	(m)	$4.05M	(m)	$0.00
2011-06-30	Reported	(m)	-$5.92M	(m)	(m)	(m)	(m)	-$8.40M*	(m)	$4.35M	(m)	$412.00K
2011-03-31	Reported	(m)	-$7.43M	(m)	(m)	(m)	(m)	-$9.04M	(m)	$5.07M	(m)	(m)
2010-09-30	Reported	(m)	-$10.54M	(m)	(m)	(m)	(m)	-$8.32M*	(m)	$7.87M	(m)	-$136.00K
2010-06-30	Reported	(m)	-$9.47M	(m)	(m)	(m)	(m)	(m)	(m)	$6.33M	(m)	$0.00

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$480.8M	(m)	(m)	(m)	42.80%	(m)	-$244.63M	(m)	$342.32M	$157.48M	$1.86M
2024-12-31	Reported	-$200.93M	(m)	(m)	(m)	-29.46%	(m)	-$87.26M	(m)	$391.17M	$337.19M	$10.88M
2023-12-31	Reported	-$525.51M	(m)	(m)	(m)	-53.42%	(m)	-$713.97M	(m)	$737.50M	$468.95M	$2.03M
2022-12-31	Reported	-$615.74M	(m)	(m)	(m)	-31.07%	(m)	-$415.94M	(m)	$1.24B	$488.69M	$4.29M
2021-12-31	Reported	-$1.67B	(m)	(m)	(m)	-146.00%	(m)	$322.95M	(m)	$2.53B	(m)	$29.21M
2020-12-31	Reported	-$412.42M	(m)	(m)	(m)	-86.72%	(m)	-$42.54M	(m)	$747.03M	(m)	$0.00
2019-12-31	Reported	-$115.48M	(m)	(m)	(m)	-618.80%	(m)	-$136.62M	(m)	$113.84M	(m)	$0.00
2018-12-31	Reported	-$166.52M	(m)	(m)	(m)	-485.65%	(m)	-$184.82M	(m)	$173.80M	(m)	(m)
2017-12-31	Reported	-$164.11M	(m)	(m)	(m)	-526.40%	(m)	-$144.48M	(m)	$168.44M	(m)	(m)
2016-12-31	Reported	-$261.41M	(m)	(m)	(m)	-1702.68%	(m)	-$258.77M	(m)	$237.94M	(m)	(m)
2015-12-31	Reported	-$152.14M	(m)	(m)	(m)	-419.69%	(m)	-$126.09M	(m)	$162.64M	(m)	$0.00
2014-12-31	Reported	-$79.29M	(m)	(m)	(m)	-258.62%	(m)	(m)	(m)	$94.42M	(m)	$0.00
2013-12-31	Reported	-$49.83M	(m)	(m)	(m)	-238.27%	(m)	(m)	(m)	$58.53M	(m)	$25.00K
2012-12-31	Reported	-$27.97M	(m)	(m)	(m)	-126.68%	(m)	-$18.23M	(m)	$26.91M	(m)	$0.00
2011-12-31	Reported	-$19.98M	(m)	(m)	(m)	-136.02%	(m)	-$23.63M	(m)	$18.36M	(m)	$412.00K
2010-12-31	Reported	-$37.09M	(m)	(m)	(m)	-10814.58%	(m)	-$32.85M	(m)	$28.03M	(m)	$450.00K
2009-12-31	Reported	(m)	-$37.38M	(m)	(m)	(m)	(m)	-$32.83M	(m)	$25.78M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Vir Biotechnology, Inc. (VIR)	United States	$1.814B	-6.85
Hemab Therapeutics Holdings, Inc. (COAG)	United States	$1.672B
Immunocore Holdings plc (IMCR)		$1.613B	-90.43
Taysha Gene Therapies, Inc. (TSHA)	United States	$1.564B	-14.80
Vericel Corp (VCEL)	United States	$2.011B	93.97
Inhibrx Biosciences, Inc. (INBX)	United States	$1.477B	-10.08
Maze Therapeutics, Inc. (MAZE)	United States	$1.457B	-12.40
RECURSION PHARMACEUTICALS, INC. (RXRX)	United States	$2.080B	-3.78
Kodiak Sciences Inc. (KOD)	United States	$2.090B	-10.12
ADMA BIOLOGICS, INC. (ADMA)	United States	$2.131B	11.16